Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval-Reference-Cited by-同舟云学术

Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval

Published:2017-06 Issue:6 Volume:5 Page:460-463
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Perez Antonio L.,Kittipibul Veraprapas,Tang W.H. Wilson,Starling Randall C.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. U.S. Food and Drug Administration. FDA News Release: FDA Approves New Drug to Treat Heart Failure. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm. Accessed March 12, 2017.

2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

3. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

4. Two-thirds of heart failure patients who meet the FDA-approved indication for sacubitril/valsartan do not meet PARADIGM-enrollment criteria after recent hospitalization;Perez;J Am Coll Cardiol,2016

5. Love of angiotensin-converting enzyme inhibitors in the time of cholera;Packer;J Am Coll Cardiol HF,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real‐world heart failure cohort;ESC Heart Failure;2023-04-24

2. Sodium–glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction;International Journal of Cardiology;2021-10

3. National Trends in the Use of Sacubitril/Valsartan;Journal of Cardiac Failure;2021-08

4. Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice;JAMA Cardiology;2021-03-01

5. Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort;ESC Heart Failure;2019-11-08